Lower Dietary and Circulating Vitamin C in Middle- and Older-Aged Men and Women Are Associated with Lower Estimated Skeletal Muscle Mass

Lucy N Lewis,1 Richard PG Hayhoe,1 Angela A Mulligan,2 Robert N Luben,3 Kay-Tee Khaw,3 and Ailsa AW e l c h1

1Department of Epidemiology and Public Health, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, United Kingdom; 2MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; and 3Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom

ABSTRACT

Background: Age-related loss of skeletal muscle mass contributes to poor outcomes including sarcopenia, physical disability, frailty, type 2 diabetes, and mortality. Vitamin C has physiological relevance to skeletal muscle and may protect it during aging, but few studies have investigated its importance in older populations.

Objectives: We aimed to investigate cross-sectional associations of dietary and plasma vitamin C with proxy measures of skeletal muscle mass in a large cohort of middle- and older-aged individuals.

Methods: We analyzed data from >13,000 men and women in the European Prospective Investigation into Cancer and Nutrition–Norfolk cohort, aged 42–82 y. Fat-free mass (FFM), as a proxy for skeletal muscle mass, was estimated using bioelectrical impedance analysis and expressed as a percentage of total mass (FFM%) or standardized by BMI (FFMBMI). Dietary vitamin C intakes were calculated from 7-d food diary data, and plasma vitamin C was measured in peripheral blood. Multivariable regression models, including relevant lifestyle, dietary, and biological covariates, were used to determine associations between FFM measures and quintiles of dietary vitamin C or insufficient compared with sufficient plasma vitamin C (<50 μmol/L and ≥50 μmol/L).

Results: Positive trends were found across quintiles of dietary vitamin C and FFM measures for both sexes, with interquintile differences in FFM% and FFMBMI of 1.0% and 2.3% for men and 1.9% and 2.9% for women, respectively (all \(P<0.001\)). Similarly, FFM% and FFMBMI measures were higher in participants with sufficient than with insufficient plasma vitamin C: by 1.6% and 2.0% in men, and 3.4% and 3.9% in women, respectively (all \(P<0.001\)). Associations were also evident in analyses stratified into <65-y and ≥65-y age groups.

Conclusions: Our findings of positive associations, of both dietary and circulating vitamin C with measures of skeletal muscle mass in middle- and older-aged men and women, suggest that dietary vitamin C intake may be useful for reducing age-related muscle loss. J Nutr 2020;150:2789–2798.

Keywords: sarcopenia, skeletal muscle, frailty, vitamin C, ascorbic acid

Introduction

Sarcopenia is characterized by a progressive and generalized loss of skeletal muscle mass and strength (1–4). Increasing age is a well-recognized risk factor for sarcopenia such that worldwide the condition affects >50 million people over the age of 50 y (2, 3). Whereas maintenance of strength and function is recognized as important for preventing functional limitations, physical disability, and loss of mobility, less recognized are the metabolic disturbances associated with loss of skeletal muscle mass (4–8). These metabolic disturbances include altered utilization of amino acids, glucose, and fatty acids, as well as contributions to the onset of obesity and type 2 diabetes (4–8). Sarcopenia and age-related skeletal muscle loss are also key contributors to frailty. Despite growing appreciation that reducing loss of skeletal mass and function with age is important, current options for prevention are limited.

The etiology of sarcopenia is multifactorial, with several contributory mechanisms including endocrine causes, age-related changes in circulating cytokines, production of reactive oxygen species (ROS), immobility, and low intakes of protein (1). ROS, which are produced during oxidative metabolism in muscle, and from age-related mitochondrial dysfunction, induce cellular damage in muscle, as does the age-related increase in...
circulating concentrations of inflammatory cytokines (9–11). Vitamin C, a water-soluble vitamin obtained by consumption of fruits, vegetables, and their products in the diet, has several mechanistic functions relevant to skeletal muscle metabolism and physiology, which could prevent age-related loss of skeletal muscle. The mechanisms for vitamin C in skeletal muscle physiology include synthesis of carnitine and collagen and recent animal studies have further elaborated the role of vitamin C deficiency (12–15). Because vitamin C is an electron donor, this may reduce oxidative damage to muscle as well as reducing the concentrations of inflammatory cytokines in the circulation (10, 11). Vitamin C deficiency, also known as scurvy, is identified by circulating concentrations of ascorbic acid $<11.4$ μmol/L, with concentrations $<50$ μmol/L considered insufficient. Evidence from validation studies indicates that these circulating concentrations are appropriate biomarkers of dietary vitamin C in epidemiological studies (16–19).

Despite knowledge of the mechanisms by which vitamin C can affect skeletal muscle physiology during aging, the importance of vitamin C in relation to skeletal muscle mass has not been extensively studied. We are unaware of previous epidemiological studies where both dietary and plasma vitamin C have been studied in relation to indexes of skeletal muscle mass in both sexes and both middle and older age, although some individual studies have been performed previously (13, 20–25). Given the relevance of vitamin C to skeletal muscle physiology and the lack of previous research on the importance of vitamin C to the sarcopenic risk factor of skeletal muscle mass, the purpose of this study was to investigate the associations of dietary and plasma vitamin C with fat-free mass (FFM) (as a proxy measure of skeletal muscle mass) in a large general population cohort of middle- and older-aged men and women. We thus investigated the cross-sectional associations between indexes of FFM and dietary intake, as well as circulating concentrations, of vitamin C, in a population of 13,000 free-living men and women in the United Kingdom in middle and older age. We also sought to determine the associations in those older and younger than 65 y of age.

Methods

Study population

The European Prospective Investigation into Cancer and Nutrition (EPIC) study is a prospective cohort involving >500,000 study participants from 10 European countries, initially designed to investigate the relations between diet and cancer. Additional outcomes have been examined within the UK EPIC-Norfolk subcohort, consisting of 25,639 men and women aged 40–79 y who attended baseline health checks between 1993 and 1997 (26). A second, follow-up, health check was attended by 17,304 participants aged 42–82 y between 1997 and 2000 in which measures of body composition were made. Our analyses were limited to 6350 men and 7989 women with complete data for dietary vitamin C analyses and 5853 men and 7212 women with complete data for plasma vitamin C analyses (see Figure 1).

Dietary assessment

Dietary intake of each participant was assessed using a 7-d food diary. The participants recorded all food and drink consumed within a 7-d period, including details of portion sizes. This method has been found to be more accurate than FFQs in estimating dietary nutrient intake when compared with weighted records (17, 27). The Data Into Nutrients for Epidemiologic Research (DINER) software used to document the dietary information provided by the 7-d food diaries and convert it into nutrient quantities has been described previously (28). Nondietary data were collected through health and lifestyle questionnaires at each health check that included questions on smoking, alcohol consumption, social class, occupational history, past history of disease, short family history of main disease endpoints, a short section on exercise, and reproductive history for women (26).

Body composition

Each participant had their height and weight measured using standard-ized methodology (26) at both health checks: height was measured to the nearest millimeter without shoes, using a freestanding stadiometer; weight was measured to the nearest 0.2 kg without shoes and in light clothing, using digital scales. Body fat was measured at the second health check using a bioelectrical impedance analysis (BIA) machine (TANITA Body Fat Monitor/Scale TBF-531), with individuals in the standing position, from which FFM (kg) was calculated as a proxy measure of skeletal muscle mass. The percentage fat-free mass (%FFM; FFM/total mass $\times 100$) and fat-free mass standardized by BMI (FFM/BMI; FFM/BMI) were calculated, as these are previously established and recommended indexes which scale for the effects of body size on the proportion of FFM (2).

Plasma vitamin C

To obtain vitamin C plasma concentrations, nonfasting blood samples were taken from participants using venipuncture. Blood samples were protected from light and without delay the plasma fraction was isolated and immediately stabilized with metaphosphoric acid. Stabilized samples were stored at −70°C and within 1 wk the plasma vitamin C concentration was estimated by fluorometric assay (29, 30).

Statistical methods

STATATA statistical software version 15 (Stata Corp.) was used to examine the relation between vitamin C and FFM. Sex differences for variables used in our analysis models were tested by independent-sample t test for continuous or chi-square test for categorical variables. Our analyses combined dietary data from health check 1, with covariate, body composition, and plasma vitamin C data from health check 2. Univariate regression was first used to investigate the differences in FFM across sex-specific quintiles (Qs) of dietary vitamin C intake. Owing to the established sex differences in body composition, all the analyses were stratified by sex. A multivariable model was then tested, incorporating biological [age; menopausal status; hormone replacement therapy (HRT) status; corticosteroid use; and statin use], lifestyle (smoking status classified as current, former, or never; social class classified by 6 categories; and physical activity status classified as inactive, moderately inactive, moderately active, and active), and dietary covariates (total energy; protein intake as a percentage of total energy; number of days participant filled in the food diary; and the ratio of energy intake to estimated energy requirement). In order to test for trends we used the median values for quintiles as a continuous variable. We also calculated the adjusted values for FFM and used these to determine the percentage differences in FFM between specific vitamin C quintiles. ANCOVA was used to determine whether these differences were statistically significant with a P value $< 0.05$. The European Food Safety Authority (EFSA) consider a serum ascorbic acid concentration
<11.4 μmol/L as deficient, <50 μmol/L as insufficient, and ≥50 μmol/L as sufficient (16, 31). Because the number classified as deficient in this cohort was small, we performed the plasma vitamin C analyses using the broader categorization of insufficiency (plasma vitamin C <50 μmol/L; n = 2035 in men and n = 1212 in women) compared with sufficiency (plasma vitamin C ≥50 μmol/L; n = 3818 in men and n = 6000 in women). Similarly to the diet analyses, we first tested an unadjusted regression model to identify any differences in indexes of FFM according to plasma vitamin C concentration. We then tested a model adjusted for age, menopausal status, HRT status, statin use, corticosteroid use, smoking, physical activity status, and social class. All models were repeated stratifying by age group (<65 y or ≥65 y). We performed additional analyses to compare the main models relating dietary vitamin C to FFM indexes, calculated with vitamin C contributions from food and drinks only, with models which also included vitamin C contributions from supplements, calculated using data from the vitamin and mineral supplement database (ViMiS) developed for EPIC-Norfolk (32). Univariate regression was used to test the association between dietary and plasma vitamin C. Exclusions were made where participants had missing values for any variables included in the multivariable model (see Figure 1). Those who had extreme BIA values (>1000 or <300 ohms), and those who had an FFM <25 kg or a BMI ≥36 kg/m², were excluded because estimating FFM from BIA including these values would be inaccurate (33). Women who were missing menopausal status had their status recoded to postmenopausal if ≥55 y and ever users of HRT, or premenopausal if <50 y and never users of HRT. Any participants missing data for smoking status were recoded as former smokers because there was higher prevalence of smoking in this cohort than in the UK population as a whole. All models were defined a priori using evidence from previous research, and thus P values < 0.05 were considered statistically significant in individual analyses.

Results

Table 1 and Supplemental Table 1 summarize participant characteristics for men and women; data are expressed as means ± SDs for continuous variables or percentages for categorical variables. There were 6350 men and 7989 women with complete data for dietary vitamin C analyses; for plasma vitamin C analyses, there were 5853 men and 7212 women. Intakes of vitamin C ranged from 36.6 ± 9.33 mg/d for men in Q1 to 170 ± 44.8 mg/d in Q5 and from 38.9 ± 9.41 mg/d for women in Q1 to 171 ± 43.4 mg/d in Q5, and mean interquintile differences were 133 and 132 mg/d, respectively. In this study 0.9% men and 0.2% of women were classified as deficient according to plasma concentrations <11.4 μmol/L and 34.7% of men and 16.8% of women were classified as insufficient (plasma concentrations <50 μmol/L).

Positive associations were found between dietary vitamin C and FFM% in both men and women (P < 0.001, n = 6350 men; and P < 0.001, n = 7989 women) after adjustment for covariates, with significant interquintile differences (Q5 compared with Q1) in FFM% of +1.0% (P < 0.001, n = 6350) in men and +1.9% (P < 0.001, n = 7989) in women (see Table 2). Similar associations were also found between vitamin C and FFM_MU (P < 0.001 for both men and women) after adjustment for covariates; and interquintile differences were significant (see Figure 2), with Q5 compared with Q1 differences in FFM_MU of +2.3% in men and +2.9% in women (all P < 0.01). Results of additional analyses including the contribution of vitamin C from supplements showed positive associations.
between total vitamin C intakes and FFM measures and no substantial differences to the results of the nonsupplement models presented here in full.

Significant differences in FFM% were found between individuals with sufficient as opposed to insufficient plasma vitamin C concentrations (P < 0.001, n = 5853 men; and P < 0.001, n = 7212 women) after adjustment for covariates (see Table 3). In the adjusted model, men who had sufficient plasma vitamin C concentrations (n = 3818) had a mean FFM% 1.6% higher than men with insufficient concentrations (n = 2035); in women the difference was 3.4% (n = 6000 sufficient compared with n = 1212 insufficient). Similarly, significant differences in FFM\textsubscript{BMI} were found between individuals with sufficient as opposed to insufficient plasma vitamin C concentrations (P < 0.001 for both men and women) after adjustment for covariates. The difference between sufficient and insufficient individuals was +2.0% for FFM\textsubscript{BMI} in men and +3.9% in women. In age-stratified analyses (<65 y and ≥65 y) (Figures 2, 3, Supplemental Tables 1–3), although the baselines for FFM measures differed between the age groups, similar significant trends to those found in all-age analyses were evident for dietary or plasma vitamin C and measurements of FFM.

### Table 1: Participant characteristics of the European Prospective Investigation into Cancer and Nutrition–Norfolk cohort population stratified by sex for the dietary vitamin C and the plasma vitamin C group

| Characteristics          | Dietary vitamin C (n = 14,339) | Plasma vitamin C (n = 13,065) |
|--------------------------|--------------------------------|--------------------------------|
|                          | Men (n = 6350)                 | Women (n = 7989)               |
|                          | Men (n = 5853)                 | Women (n = 7212)               |
| Age, y                   | 62.9 ± 9.03                    | 61.5 ± 9.04                    |
| BMI, kg/m\(^2\)          | 26.7 ± 3.05                    | 26.1 ± 3.73                    |
| Weight, kg               | 80.9 ± 10.8                    | 67.7 ± 10.4                    |
| Height, cm               | 174 ± 6.61                     | 161 ± 6.12                     |
| FFM%                     | 76.7 ± 5.78                    | 60.9 ± 8.25                    |
| FFM\textsubscript{BMI}, kg/m\(^2\) | 2.33 ± 0.257              | 1.58 ± 0.259                   |
| Vitamin C intake, mg/d   | 89.8 ± 50.7                    | 93.7 ± 50.1                    |
| Plasmavitamin C, μmol/L  | —                              | —                             |
| Protein, g/d             | 83.4 ± 17.6                    | 66.2 ± 13.7                    |
| Protein, % energy        | 14.8 ± 2.40                    | 15.5 ± 2.77                    |
| Energy intake, kcal/d    | 2286 ± 500                     | 1735 ± 378                     |
| Smoking                  |                                |                                |
| Current                  | 8.54 (542)                     | 8.71 (4695)                    |
| Former                   | 55.5 (3524)                    | 31.9 (2551)                    |
| Never                    | 34.0 (2284)                    | 59.4 (4742)                    |
| Physical activity        |                                |                                |
| Inactive                 | 27.3 (1736)                    | 25.9 (1566)                    |
| Moderately inactive      | 25.1 (1595)                    | 32.5 (1458)                    |
| Moderately active        | 25.0 (1590)                    | 24.2 (1393)                    |
| Active                   | 22.5 (1429)                    | 17.3 (1386)                    |
| Corticosteroid use       |                                |                                |
| Current                  | 4.16 (264)                     | 5.09 (407)                     |
| Menopausal status        |                                |                                |
| Premenopausal            | —                              | —                              |
| Perimenopausal ≤1 y      | —                              | 5.95 (475)                     |
| Perimenopausal 1–5 y     | —                              | 3.33 (266)                     |
| Postmenopausal >5 y      | —                              | 17.5 (1399)                    |
| HRT use                  |                                |                                |
| Current                  | —                              | 21.3 (1704)                    |
| Former                   | —                              | 17.9 (1431)                    |
| Never                    | —                              | 60.8 (4854)                    |
| Statins use              |                                |                                |
| Yes                      | 5.46 (347)                     | 3.63 (290)                     |
| Days participant filled in diary, n | 6.75 ± 1.16 | 6.81 ± 1.01 | 6.75 ± 1.15 | 6.81 ± 1.01 |
| Vitamin C supplementation|                                |                                |
| Yes                      | 34.5 (695)                     | 39.8 (1425)                    |
| Social class             |                                |                                |
| Professional             | 8.24 (623)                     | 8.83 (546)                     |
| Managerial               | 40.7 (2587)                    | 36.9 (2950)                    |
| Skilled nonmanual        | 12.6 (797)                     | 19.4 (1554)                    |
| Skilled manual           | 22.4 (1422)                    | 19.7 (1577)                    |
| Semiskilled              | 12.5 (781)                     | 11.9 (950)                     |
| Nonskilled               | 2.35 (149)                     | 3.34 (267)                     |

1Values are means ± SDs or % (n): Differences between men and women for all characteristics had P values < 0.01, according to t test for continuous or chi-square test for categorical variables. FFM\textsubscript{BMI}, fat-free mass standardized by BMI; FFM%, fat-free mass percentage; HRT, hormone replacement therapy.
Results from the univariate regression between dietary and plasma vitamin C in the whole cohort population showed that for every 1-mg increase in vitamin C intake per day there was an increase in plasma vitamin C concentration of 0.478 μmol/L. (P < 0.001, n = 13,033). The rate was greater in men than in women: 0.647 μmol·L⁻¹·mg⁻¹ increase in men (P < 0.001, n = 5832) and 0.392 μmol·L⁻¹·mg⁻¹ increase in women (P < 0.001, n = 7201).

The greatest percentage contributions of different food groups to the daily vitamin C intake of the population were from fruits, vegetables, potatoes, and fruit juices (84.4% of the total intake in men and 87.1% in women) (Figure 4). Overall, the greatest contribution to vitamin C intake was from fruit intake (26.5% in men and 32% in women), followed by vegetables (25.2% for both sexes).

Discussion

To our knowledge, this is the first study assessing the relation of dietary and circulating vitamin C with the sarcopenic risk factor of loss of skeletal muscle mass in a large UK cohort of both men and women of middle and older age. Our results show significant positive associations between dietary vitamin C intake and measures of FFM (as proxies for skeletal muscle mass) using multivariable regression models, adjusted for known lifestyle and biological covariates. The magnitude of differences seen with the indexes of FFM between individuals with intakes of vitamin C in the lowest and highest quintiles was greater for FFM_BMI than for FFM%, with the largest difference of 2.9% seen in FFM_BMI of women. Importantly, our findings with dietary vitamin C intake values derived from self-reported food diary data were reinforced and validated by our analyses using biomarker data. These showed similar trends and strong associations of circulating vitamin C and indexes of FFM, with statistically significant differences between sufficient and insufficient concentrations, with the largest difference of 3.9% seen in FFM_BMI of women. Although associations were significant for both sexes, the scale of the associations was greater in women than in men. Similar associations were seen in age-stratified analyses for those above and below 65 y of age, although the magnitude of differences in FFM measures varied by age group. Previous studies have shown that people over the age of 50 y experience a 0.5%–1% loss of muscle mass per year (34), thus suggesting, by comparison, that the magnitude of the differences seen in our analyses could be of clinical importance.

Only a small number of previous studies have investigated associations between either dietary or circulating vitamin C concentrations and indexes of skeletal muscle mass or function (20–25).

Of the 3 previous cohort studies investigating indexes of skeletal muscle mass and vitamin C, 2 found significant differences in skeletal muscle mass measures ranging from 1% to 3.2% between extreme quintiles of vitamin C intake in women, and differences ≤3.5% across quartiles of vitamin C intake in men and women over a follow-up period of 2.6 y (23, 25); the third found no associations between skeletal muscle mass measures and plasma vitamin C concentrations (20). Three other studies found no association between intake of vitamin C and prevalence of sarcopenia (35–37). All these previous studies investigating either dietary or circulating vitamin C and FFM, muscle function, or sarcopenia were in smaller populations than in our study and none investigated associations in a mixed population stratified by sex (20–25, 35–37).

Mechanisms

The mechanistic roles for vitamin C in skeletal muscle physiology include the synthesis of carnitine and collagen. These are important because collagen is a key structural component of skeletal muscle cells and tendons, and carnitine is essential for the transport of long-chain fatty acids into the mitochondria. Vitamin C also plays a role in the synthesis of proline, an amino acid that is a key component of collagen. Additionally, vitamin C has antioxidant properties, which can help protect muscle cells from oxidative stress, a factor that contributes to muscle loss. Furthermore, vitamin C is involved in the production of collagen, which is a major component of skeletal muscle tissue. The synthesis of collagen requires the presence of vitamin C, and low levels of vitamin C can lead to a decrease in collagen production, resulting in weaker and more fragile muscle tissue.
for metabolism of long-chain fatty acids during physical activity (14, 15). Animal studies have further elucidated the mechanisms relating to skeletal muscle atrophy, and the morphological changes caused by deficiency of dietary vitamin C. The main drivers appear to be upregulation of the ubiquitin ligases atrogin1/muscleatrophyF-boxandmuscleRING-fingerprotein 1 and a reduction in production of ROS (12–15). Moreover, muscle atrophy was reversed by reintroduction of vitamin C into the diet in 1 of these studies (12).

**Deficiency and low intakes**

In general terms, the prevalence of vitamin C deficiency is greater in men than in women and is high in low-income and vulnerable populations in care (38–41). Whereas the prevalence

### TABLE 3 **Associations between plasma vitamin C concentration (insufficient: < 50 μmol/L and sufficient: ≥ 50 μmol/L) and skeletal muscle mass in men and women aged 42–82 y**

| Vitamin C categories | Dietary vitamin C | Plasma vitamin C | FFM% | FFM_{BMI} | Unadjusted Adjusted | Unadjusted Adjusted |
|----------------------|------------------|------------------|------|----------|---------------------|---------------------|
|                      | Mean ± SD | Median | Mean ± SD | Median |                   |                     |
| Men (n = 5853)       |           |       |           |       |                   |                     |
| Insufficient (n = 2035) | 72.9 ± 39.7 | 63.4  | 35.9 ± 10.8 | 39.0  | 75.9 ± 0.131 | 75.9 ± 0.126  | 2.29 ± 0.006 | 2.30 ± 0.006 |
| Sufficient (n = 3818) | 99.0 ± 53.3 | 88.0  | 68.1 ± 16.5 | 84.0  | 77.2 ± 0.090 | 77.2 ± 0.092  | 2.35 ± 0.004 | 2.34 ± 0.004 |
| Absolute difference 2 | —       | —     | —       | —     | 1.29 (0.980, 1.59) | 1.25 (0.943, 1.56) | 0.060 (0.046, | 0.047 (0.033, 0.073) | 0.061 |
| % difference 3       | —       | —     | —       | —     | 1.70       | 1.65         | 2.61        | 2.05 |
| *P value*            | —       | —     | —       | —     | <0.001    | <0.001       | <0.001      | <0.001 |
| Women (n = 7212)     |           |       |           |       |                   |                     |
| Insufficient (n = 1212) | 73.1 ± 40.6 | 63.8  | 37.1 ± 10.1 | 40.0  | 59.3 ± 0.260 | 59.3 ± 0.235  | 1.53 ± 0.008 | 1.54 ± 0.007 |
| Sufficient (n = 6000) | 98.2 ± 51.0 | 88.4  | 75.4 ± 21.4 | 72.0  | 61.3 ± 0.103 | 61.3 ± 0.104  | 1.60 ± 0.003 | 1.60 ± 0.003 |
| Absolute difference 2 | —       | —     | —       | —     | 2.03 (1.53, 2.54) | 2.03 (1.53, 2.54) | 0.068 (0.052, | 0.060 (0.044, 0.084) | 0.076 |
| % difference 3       | —       | —     | —       | —     | 3.43       | 3.43         | 4.43        | 3.91 |
| *P value*            | —       | —     | —       | —     | <0.001    | <0.001       | <0.001      | <0.001 |

1 Values are means ± SEMs. *P* values were calculated using ANCOVA comparing the 2 categories. Adjusted model includes age, smoking status, physical activity, corticosteroid use, menopausal status, hormone replacement therapy use, statins use, and social class. FFM_{BMI}, fat-free mass standardized by BMI; FFM%, fat-free mass percentage.

2 Absolute difference calculates the absolute difference between means of the 2 categories, with 95% CIs.

3 % difference calculates the percentage difference between means of the 2 categories.
FIGURE 3  Adjusted FFM measures for individuals of the European Prospective Investigation into Cancer and Nutrition–Norfolk cohort stratified by sex (men (A); women (B)), age group, and plasma categories of vitamin C (<50 μmol/L and ≥50 μmol/L) (n = 13,065).

∗∗∗Significant difference with insufficient, according to ANCOVA: ∗∗P < 0.01; ∗∗∗P < 0.001. Adjusted model includes age, smoking status, physical activity, corticosteroid use, menopausal status, hormone replacement therapy use, statins use, and social class. Values are presented as means with SEMs as error bars. Men <65 y: insufficient, n = 1038; sufficient, n = 2171. Men ≥65 y: insufficient, n = 997; sufficient, n = 1647. Women <65 y: insufficient, n = 668; sufficient, n = 3745. Women ≥65 y: insufficient, n = 544; sufficient, n = 2255. FFM, fat-free mass; FFMBMI, fat-free mass standardized by BMI; FFM%, fat-free mass percentage.

of very low plasma concentrations of vitamin C, indicative of scurvy, in our cohort population was 0.9% in men and 0.2% in women, more than one-third of men (35%) and one-sixth of women (17%) were vitamin C insufficient. Within the United States 14% of men and 8% of women of a similar age to those in our study are deficient (42), and the prevalence of insufficiency in the UK population, as a whole, is 57% in men and 39% in women (41). In terms of the dietary guidelines for vitamin C, these range from the older UK guidelines with a recommended UK estimated average requirement (EAR) of 40 mg/d to the EFSA guidelines of 90 mg/d in men and 80 mg/d in women (16, 43, 44). Within our cohort 11% of men and 10% of women had intakes of vitamin C below the UK EAR, with the equivalent proportions for the EFSA guidelines being 59% in men and 47% in women. In our study, only those people in Q4 and Q5 of vitamin C intake consumed amounts at or above the EFSA guidelines, indicating that 60% of the population were consuming insufficient vitamin C.

Given that we found potentially clinically significant effects of insufficient dietary and circulating vitamin C on FFM, strategies to reduce the proportion of individuals with insufficient vitamin C status by increasing vitamin C intake may be beneficial for skeletal muscle health at a population level. This suggestion is also supported by a previous dietary supplementation intervention study where increased intake of vitamin C was associated with an increase in concentration of vitamin C in plasma, but also in the vastus lateralis (the largest of the quadriceps leg muscles) (45).

Analysis of dietary data for our cohort showed that for both men and women the greatest contributors to vitamin C intake were fruits, vegetables, potatoes, and fruit juices (Figure 4). Although such foods are typically readily available and easy to prepare and small increases in daily consumption should be achievable, limitations in income, access, and availability exist in at-risk populations. In our cohort the mean interquintile differences in vitamin C intakes for men and women were 133 and 132 mg/d, respectively, a >4-fold difference between Q1 and Q5. The individuals in Q1, consuming a mean of ~40 mg/d, would need to consume the equivalent of 1 citrus fruit (e.g., an orange), a glass of apple juice, and a vegetable accompaniment with a meal (e.g., cabbage or broccoli) to achieve the same vitamin C intake as individuals in Q5.

Strengths and limitations
We believe our study is a significant advance on previous research in this area and has a number of particular strengths. This is the largest study to examine concurrent associations of dietary and plasma vitamin C with measures of skeletal muscle (FFM% and FFMBMI) in both men and women of both middle and older age (20–25). Dietary intakes were calculated using 7-d food diaries. This method provides more accurate estimates of vitamin C than FFQs, which have been shown to systematically estimate intakes of vitamin C as ~50% higher than the time-dependent methods of 7-d diaries or 24-h recalls (17, 46). The use of plasma vitamin C in this study is advantageous...
because this measurement accounts for factors that affect the absorption and metabolism of dietary vitamin C (e.g., current smoking habit). This helps to validate our findings because plasma vitamin C is a good biomarker of vegetable and fruit consumption and avoids the potential reporting bias in using dietary intake records (17, 18). However, blood samples were taken from nonfasted participants and thus steady-state vitamin concentrations may have been overestimated. We adjusted for recognized risk factors and lifestyle variables, including protein intake, that are known to affect skeletal muscle mass.

To acknowledge any potential contribution of vitamin C supplementation, in parallel analyses we tested models with and without supplementation data and found that supplementation did not materially alter our findings. A general limitation of our study is the cross-sectional design, which means we cannot infer a causative link between vitamin C intake and skeletal muscle mass measures, and we cannot assess the temporality of associations. Dietary data were derived from food intake only, and thus excluded supplements; however, when we tested the quantitative contribution of vitamin C supplementation there were no significant changes to our findings. BIA was used to measure body composition, which is regarded to be less precise than DXA measurements. However in healthy individuals, BIA is considered as an accurate, practical, noninvasive data collection method, for measurements of body composition when compared with the more precise DXA method (47, 48). For sarcopenia diagnosis both low muscle mass and low muscle function are expected, but presarcopenia (itself a major risk factor for sarcopenia) is characterized by low muscle mass without overt effects on muscle function (3). The metabolic consequences of loss of skeletal muscle are also potentially important for sarcopenia (4). Thus, although muscle function data were not available for our analyses, our study investigating FFM as an estimate of skeletal muscle mass is still valuable for understanding risk of sarcopenia. Our analyses were conducted on a generally healthy population cohort and we did not adjust our analyses for chronic disease status which may influence sarcopenia outcomes. Lastly, the EPIC-Norfolk cohort is a population from a geographically defined area, with little outward migration, and consisting mainly of Caucasian participants, thus our results may be less applicable to different ethnic groups.

Overall, our findings suggest that consuming a diet high in vitamin C has potential for protection of skeletal muscle health during aging and thereby provides reinforcement to the benefits of following healthy eating guidelines by consuming sufficient fruits and vegetables. Further studies are required that include longitudinal analyses and intervention trials to investigate the long-term effects of increasing dietary or supplemental vitamin C on skeletal muscle health during aging.

**Conclusion**

This study has shown significant positive associations between both dietary and circulating vitamin C and measures of skeletal muscle in a large cohort of free-living middle- and older-aged men and women. These results suggest that ensuring sufficient
dietary vitamin C intake, by promoting a diet rich in fruits and vegetables, may help to reduce age-related loss of skeletal muscle and thus have wide-reaching public health benefit.

Acknowledgments

The authors’ responsibilities were as follows—AAW: developed the research question under discussion with LNL and RPH; organized data collection with RNL, and was responsible for the final content; RPHG: devised and conducted the data analyses; LNL: drafted the manuscript after data interpretation in conjunction with RPHG and AAW who also edited the manuscript; AAM and AAW: were involved in nutritional database and dietary assessment development; K-TK: was the principal investigator of the EPIC-Norfolk Study; and all authors: read and approved the final manuscript. The EPIC datasets used in our analyses are available to other researchers by request to the EPIC team at the University of Cambridge.

References

1. Landi F, Camprubi-Robles M, Bear DE, Cederholm T, Malafarina V, Welch AA, Cruz-Jentoft AJ. Muscle loss: the new malnutrition challenge in clinical practice. Clin Nutr 2019;38:2113–20.
2. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31.
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 2010;39:412–23.
4. Welch AA, Hayhoe RPG, Cameron D. The relationships between sarcopenic skeletal muscle mass loss during ageing and macronutrient metabolism, obesity and onset of diabetes. Proc Nutr Soc 2020;79:158–69.
5. Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, Woo J, Baumgartner RN, Pillard F, Boirie Y, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12:433–50.
6. Morley JE. Sarcopenia: diagnosis and treatment. J Nutr Health Aging 2010;14:452–6.
7. Argiles JM, Campos N, Lopez-Pedrosa JM, Rubia R, Rodriguez-Mana L. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc 2016;17:789–96.
8. Welch AA. Nutritional influences on age-related skeletal muscle mass. Proc Nutr Soc 2014;73:16–33.
9. Gomes MJ, Martinez PF, Pagan LU, Damatto RL, Cezar MDM, Lima ARR, Okoshi K, Okoshi MP. Skeletal muscle aging: influence of oxidative stress and physical exercise. Oncotarget 2017;8:20428–40.
10. Dalle S, Rossmeislova L, Koppo K. The role of inflammation in age-related sarcopenia. Front Physiol 2017;8:1045.
11. Cerullo F, Gambassi G, Cesari M. Rationale for antioxidant supplementation in sarcopenia. J Aging Res 2012;316943.
12. Takasawa S, Funakoshi T, Yatsu T, Nagata K, Aigaki T, Machida S, Ishigami A. Vitamin C deficiency causes muscle atrophy and a deterioration in physical performance. Sci Rep 2019;9:4702.
13. Ryan MJ, Duddash HJ, Docherty M, Geronilla KB, Baker BA, Haff GG, Cutlip RG, Alway SE. Vitamin E and supplementation reduces oxidative stress, improves antioxidant enzymes and positive muscle mass in chronically loaded muscles of aged rats. Exp Gerontol 2010;45:882–95.
14. Chapman MA, Meza R, Lieber RL. Skeletal muscle fibroblasts in health and disease. Differentiation 2016;92:108–15.
15. Rebouche CJ. Ascorbic acid and carnitine biosynthesis. Am J Clin Nutr 1991;54:1147S–52S.
16. EFSA. Scientific opinion on dietary reference values for vitamin C. EFSA J 2013;11(6):3265.
17. Bingham SA, Gill C, Welch A, Cassidy A, Runswick SA, Oakes S, Lubin R, Thornham DI, Key TJ, Roe L, et al. Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int J Epidemiol 1997;26(Suppl 1):S137–51.
18. Bingham S, Luben R, Welch A, Low YL, Khaw KT, Wareham N, Day N. Associations between dietary methods and biomarkers, and between fruits and vegetables and risk of ischaemic heart disease, in the EPIC Norfolk Cohort Study. Int J Epidemiol 2008;37:978–87.
19. Sinha R, Block G, Taylor PR. Determinants of plasma ascorbic acid in a healthy male population. Cancer Epidemiol Biomarkers Prev 1992;1:297–302.
20. Saito K, Yokoyama T, Yoshida H, Kim H, Shimada H, Yoshida Y, Iwasa H, Shimizu Y, Kondo Y, Handa S, et al. A significant relationship between plasma vitamin C concentration and physical performance among Japanese elderly women. J Gerontol A Biol Sci Med Sci 2012;67:295–301.
21. Cesari M, Palmar M, Bartali B, Cherubini A, Pennix BW, Williams GR, Atkinson H, Martin A, Guralnik JM, Ferrucci L. Antioxidants and physical performance in elderly persons: the InCHIANTI study. Am J Clin Nutr 2004;79:288–94.
22. Tak YJ, Lee JG, Yi YH, Kim YJ, Lee S, Cho BM, Cho YH. Association of handgrip strength with dietary intake in the Korean population: findings based on the seventh Korea National Health and Nutrition Examination Survey (KNHANES VII-1), 2016. Nutrients 2018;10:1180.
23. Scott D, Blizzard L, Fell J, Gilles G, Jones G. Associations between dietary nutrient intake and muscle mass and strength in community-dwelling older adults: the Tasmanian Older Adult Cohort Study. J Am Geriatr Soc 2010;58:2129–34.
24. Robinson SM, Jameson KA, Batelaan SF, Martin HJ, Syddall HE, Dennison EM, Cooper C, Sayer AA, Hertfordshire Cohort Study Group. Diet and its relationship with grip strength in community-dwelling older men and women: the Hertfordshire Cohort Study. J Am Geriatr Soc 2008;56:84–90.
25. Welch AA, Jennings A, Kaeliditi E, Skinner J, Steves CJ. Cross-sectional associations between dietary antioxidant vitamins C, E and carotenoid intakes and sarcopenic indices in women aged 18–79 years. Calcif Tissue Int 2020;106:331–42.
26. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80(Suppl 1):95–103.
27. Day N, McKeown N, Wong M, Welch A, Bingham S. Epidemiological assessment of diet: a comparison of a 7-day diary with a food frequency questionnaire using urinary markers of nitrogen, potassium and sodium. Int J Epidemiol 2001;30:309–17.
28. Welch AA, McTaggart A, Mulligan AA, Luben R, Walker N, Khaw KT, Day NE, Bingham SA. DINNER (Data Into Nutrients for Epidemiological Research) – a new data-entry program for nutritional analysis in the EPIC–Norfolk cohort and the 7-day diary method. Public Health Nutr 2001;4:1253–65.
29. Key T, Oakes S, Davey G, Moore J, Edmond LM, McLoone UJ, Thornham DI. Stability of vitamins A, C, and E, carotenoids, lipids, and testosterone in whole blood stored at 4 degrees C for 6 and 24 hours before separation of serum and plasma. Cancer Epidemiol Biomarkers Prev 1996;5:811–4.
30. Vuijleumier J, Keck E. Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment. J Micronut Anal 1989;5:25–34.
31. Noble JM, Patterson MC. Vitamin C deficiency - symptoms, diagnosis and treatment. [Accessed 2020 Jul 24]. Available from: http://bestprac tice.bmj.com/topics/en-gb/632. BMJ Best Practice2020.
32. Lentjes MA, Bihanani A, Mulligan AA, Khaw K-T, Welch AA. Developing a database of vitamin and mineral supplements (ViMS) for the Norfolk arm of the European Prospective Investigation into Cancer (EPIC-Norfolk). Public Health Nutr 2011;14:459–71.
33. Fransen FM, Rutten EP, Groenen MT, Vanferlenet LE, Wouters EF, Spronk MA. New reference values for body composition by bioelectrical impedance analysis in the general population: results from the UK Biobank. J Am Med Dir Assoc 2014;15:448.e1–6.
34. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human

Vitamin C associations with fat-free mass 2797
skeletal muscle size and strength; a quantitative review. Front Physiol 2012;3:260.

35. Verlaan S, Aspray TJ, Bauer JM, Cederholm T, Hemsworth J, Hill TR, McPhee JS, Piasecki M, Seal C, Sieber CC, et al. Nutritional status, body composition, and quality of life in community-dwelling sarcopenic and non-sarcopenic older adults: a case-control study. Clin Nutr 2017;36:267–74.

36. Ter Borg S, de Groot LC, Mijnarends DM, de Vries JH, Verlaan S, Meijboom S, Luiking YC, Schols JM. Differences in nutrient intake and biochemical nutrient status between sarcopenic and non-sarcopenic older adults—results from the Maastricht Sarcopenia Study. J Am Med Dir Assoc 2016;17:393–401.

37. Chaput JP, Lord C, Cloutier M, Aubertin Leheudre M, Goulet ED, Rousseau S, Khalil A, Dionne IJ. Relationship between antioxidant intakes and class I sarcopenia in elderly men and women. J Nutr Health Aging 2007;11:363–9.

38. Bunn D, Hooper L, Welch A. Dehydration and malnutrition in residential care: recommendations for strategies for improving practice derived from a scoping review of existing policies and guidelines. Geriatrics (Basel) 2018;3:77.

39. Mosdol A, Erens B, Brunner EJ. Estimated prevalence and predictors of vitamin C deficiency within UK’s low-income population. J Public Health (Oxf) 2008;30:456–60.

40. Schleicher RL, Carroll MD, Ford ES, Lacher DA. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003–2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr 2009;90:1252–63.

41. Public Health England. National Diet and Nutrition Survey: years 1 to 9 of the Rolling Programme (2008/2009 – 2016/2017). Report. London: Public Health England; 2019.

42. Hampi JS, Taylor CA, Johnston CS. Vitamin C deficiency and depletion in the United States: the Third National Health and Nutrition Examination Survey, 1988 to 1994. Am J Public Health 2004;94:870–5.

43. US Department of Health and Human Services, USDA, US Dietary Guidelines Advisory Committee. Dietary guidelines for Americans, 2010. 7th ed. Washington (DC): GPO; 2010.

44. Committee on Medical Aspects of Food Policy, Panel on Dietary Reference Values, Great Britain Department of Health. Dietary reference values for food energy and nutrients for the United Kingdom: report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy. London: TSO; 1991.

45. Carr AC, Bozinet SM, Pullar JM, Simcock JW, Vissers MC. Human skeletal muscle ascorbate is highly responsive to changes in vitamin C intake and plasma concentrations. Am J Clin Nutr 2013;97:800–7.

46. Dehghan M, Akhtar-Danesh N, McMillan CR, Thabane L. Is plasma vitamin C an appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. Nutr J 2007;6:41.

47. Cawthon PM. Assessment of lean mass and physical performance in sarcopenia. J Clin Densitom 2015;18:467–71.

48. Ramel A, Geirsdottir OG, Arnarson A, Thorsdottir I. Regional and total body bioelectrical impedance analysis compared with DXA in Icelandic elderly. Eur J Clin Nutr 2011;65:978–83.